高盛:維持中生製藥(1177.HK)"買入"評級 目標價10.2港元
高盛發表研究報吿指,中國生物製藥(1177.HK)第二季銷售按年升10.7%至71億元(人民幣,下同),略低於該行預期,當中腫瘤及骨科藥物增長放慢;上半年純利按年升5.84倍至85億元,勝預期。該行維持其"買入"評級,目標價由11.8港元下調13.56%至10.2港元。
該行認為,疫苗業務將繼續推動今年盈利增長,不過該行聚焦更多在其核心療法業務發展。該行將其2021-23年純利預測分別上調74.3%、7.8%及8.3%,以反映疫苗業務盈利貢獻,及核心業務更好的毛利率,不過將其2021-26年複合年增長率由18%下調至10%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.